Coherus Oncology (CHRS) Non-Current Assets (2013 - 2026)
Coherus Oncology (CHRS) posted Non-Current Assets of $60.0 million for Q1 2026, up 16.17% sequentially from $51.6 million in Q4 2025, and down 1.48% YoY from $60.9 million in Q1 2025.
Coherus Oncology (CHRS) Non-Current Assets (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Non-Current Assets for 14 years, with the latest figure at $60.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.48% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.4 million (down 46.18% YoY) and the FY2025 annual result came in at $51.6 million, down 51.72% from the prior year.
- Non-Current Assets improved to $60.0 million in Q1 2026 per CHRS's latest filing, from $51.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $154.0 million in Q4 2023 and troughed at $51.6 million in Q4 2025.
- A 5-year average of $95.9 million and a median of $99.2 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 57.3% in 2024, then sank 59.14% in 2025.
- Over 5 years, Non-Current Assets stood at $99.6 million in 2022, then soared by 54.57% to $154.0 million in 2023, then slumped by 30.54% to $107.0 million in 2024, then slumped by 51.72% to $51.6 million in 2025, then rose by 16.17% to $60.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $60.0 million, $51.6 million, and $55.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 18.06 Bn |
| 10 | Coherus Oncology | 216.74 Mn | 111.44 Mn | 10.07 Mn | 57.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.40 Mn |
| Mar 31, 2026 | 59.99 Mn |
| Dec 31, 2025 | 51.64 Mn |
| Sep 30, 2025 | 55.56 Mn |
| Jun 30, 2025 | 59.26 Mn |
| Mar 31, 2025 | 60.89 Mn |
| Dec 31, 2024 | 106.95 Mn |
| Sep 30, 2024 | 135.98 Mn |
| Jun 30, 2024 | 116.92 Mn |
| Mar 31, 2024 | 136.07 Mn |
| Dec 31, 2023 | 153.97 Mn |
| Sep 30, 2023 | 139.42 Mn |
| Jun 30, 2023 | 84.11 Mn |
| Mar 31, 2023 | 86.50 Mn |
| Dec 31, 2022 | 99.61 Mn |
| Sep 30, 2022 | 102.63 Mn |
| Jun 30, 2022 | 99.22 Mn |
| Mar 31, 2022 | 80.94 Mn |
| Dec 31, 2021 | 77.01 Mn |
| Sep 30, 2021 | 68.69 Mn |